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Available online 21 June 2016Hepatitis C virus (HCV) can cause persistent infection and chronic liver disease, and viral factors are involved in
HCV persistence. HCV core protein, a highly conserved viral protein, not only elicits an immunoresponse, but it
also regulates it. In addition, HCV core protein interacts with toll-like receptors (TLRs) on monocytes, inducing
them to produce cytokines. Polyinosinic acid:polycytodylic acid (polyI:C) is a synthetic analogue of double-
stranded RNA that binds to TLR3 and can induce secretion of type I IFN from monocytes. Cytokine response
against HCV is likely to affect the natural course of infection aswell as HCV persistence. However, possible effects
of cytokines induced by HCV core protein and polyI:C remain to be investigated. In this study, we isolated CD14+
monocytes from healthy donors, cultured them in the presence of HCV core protein and/or polyI:C, and charac-
terized the induced cytokines, phenotypes and mechanisms. We demonstrated that HCV core protein- and
polyI:C-stimulated CD14+ monocytes secreted tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-10, and
type I interferon (IFN). Importantly, TNF-α and IL-1β regulated the secretion of IL-10, which then influenced
the expression of signal transducer and activator of transcription 1 (STAT1) and interferon regulatory factor 1
(IRF1) and subsequently the production of type I IFN. Interestingly, type I IFN also regulated the production of
IL-10, which in turn inhibited the nuclear factor (NF)-κB subunit, reducing TNF-α and IL-1β levels. Therefore,







Hepatitis C virus (HCV) infection in the majority of affected individ-
uals becomes chronic, and the mechanisms responsible for persistent
HCV infection are not completely understood. It has been suggested
that the host's insufficient immune response and particularly weak cel-
lular immunity lead to viral persistence [1,2]. However, viral factors are
also involved in HCV pathogenesis.
Accumulating evidence suggests that HCV proteins can suppress the
host's immune responses by interferingwith immune cell functions [3–
5]. The core protein is a highly conserved structural protein that is re-
quired to assemble the viral nucleocapsid, which encapsulates the
viral RNA genome. HCV core protein also interacts with HCV envelope
proteins to initiate virus particle assembly [6,7]. In addition, it regulates
cellular transcription, transformation, signal transduction, and innatengkuntu2013@126.com (Z. Tu).immunity. Moreover, HCV core protein is believed to engage in virus-
mediated pathogenesis through modulating apoptosis, cell growth,
and reactive oxygen species production [6,8]. HCV core-dependent de-
regulation of the Janus kinase-signal transducer and activator of tran-
scription (STAT) signaling pathway, which suppresses HCV-induced
innate immunity, has been suggested [9–11].
Monocytes are important immune cells that defend the host against
numerous pathogens as well as initiate and control adaptive immunity
[12]. These cells express a panel of receptors including toll-like recep-
tors (TLRs), which bind to diverse pathogen-derived products, thus trig-
gering the immune response to a broad range of bacterial and viral
pathogens [13,14]. HCV core protein and double-stranded RNA can in-
teract with TLR2 and TLR3 on monocytes and induce large quantities
of proinflammatory and anti-inflammatory cytokines, which may lead
to hepatic inflammation that can facilitate HCV infection clearance.
Peripheralmonocytes produce interleukin (IL)-10, which can inhibit
the HCV immune response [15,16]. The IL-10 level has been associated
with an elevated serum alanine transaminase and/or histological
Table 1
Primers used for qPCR analysis of gene expression.
Gene Primers Product size
GAPDH PF: 5′-CCACCTTTGACGCTGGG-3′ 66 bp
PR: 5′-CATACCAGGAAATGAGCTTGACA-3′
IL-10 PF: 5′-GGGAGAACCTGAAGACCCTCA-3′ 72 bp
PR: 5′-TGCTCTTGTTTTCACAGGGAAG-3′
TNF-α PF: 5′-ATCCTGGGGGACCCAATGTA-3′ 112 bp
PR: 5′-AAAAGAAGGCACAGAGGCCA-3′
IL-1β PF: 5′-CAGAAGTACCTGAGCTCGCC-3′ 153 bp
PR: 5′-AGATTCGTAGCTGGATGCCG-3′
IFN-β PF: 5′-TGGCTGGAATGAGACTATTGTTGAG-3′ 76 bp
PR: 5′-CAGGACTGTCTTCAGATGGTTTATCT-3′
STAT1 PF: 5′-CGGCTGAATTTCGGCACCT-3′ 81 bp
PR:5′-CAGTAACGATGAGAGGACCCT-3′
STAT3 PF: 5′-ATTGCCCGGATTGTGGCCCG-3′ 117 bp
PR: 5′-CTCCGTCACCACGGCTGCTG-3′
IRF1 PF: 5′-AAAAGGAGCCAGATCCCAAGA-3′ 128 bp
PR: 5′-CATCCGGTACACTCGCACAG-3′
NFκB PF: 5′-TGGGCTACACCGAAGCAAT-3′ 69 bp
PR: 5′-GGGCCTGAGAGGTGGTCTT-3′grade in HCV patients [17]. In addition, it has been correlated with out-
comes of chronic viral infection [18]. One study has revealed that type I
interferon (IFN) can induce IL-10 production and the subsequent STAT3
phosphorylation, thus further inhibiting the expression of proinflam-
matory cytokines including IL-1β, tumor necrosis factor-α (TNF-α),
and IL-12 [19]. It is unclear whether proinflammatory cytokines regu-
late the IL-10 level and functions or further modulate type I IFN expres-
sion. In this study, we investigated the responses of monocytes to HCV
core protein and polyinosinic acid:polycytodylic acid (polyI:C) which
could simulate HCV RNA. And we showed that proinflammatory cyto-
kines induce the upregulation of IL-10 and the subsequent inhibition
of type I IFN production, in turn, type I IFN increase the secretion of IL-
10 and then inhibits proinflammatory cytokines production. IL-10 ap-
pears to play a central role in the regulatory network of inflammatory
and antiviral cytokines.
2. Materials and methods
2.1. Reagents
We purchased the experimental reagents from the following
sources: HCV Core Antigen [amino acids 2–192] Recombinant and β-
galactosidase (Meridian Life Science, Inc., Saco, ME, USA); polyI:C
(Invivogen, San Diego, CA, USA); anti-human IL-10 Functional Grade
Purified, Anti-Human TNF alpha Functional Grade Purified, Anti-
Human IL-1 beta Functional Grade Purified, Anti-Human IFN beta Func-
tional Grade Purified, and Anti-Human IFN-α (eBioscience, San Diego,
CA, USA); human IL-10 ELISA ready-SET-Go, human TNF alpha ELISA
ready-SET-Go, human IL-1 beta ELISA ready-SET-Go (eBioscience, San
Diego, CA, USA); VeriKine TM Human Interferon beta/alpha ELISA Kit
(PBL Assay Science, Piscataway, NJ, USA); CD14 microbeads (Miltenyi
Biotec, Inc., Auburn, CA, USA); PE/Cy7-conjugated anti-human HLA-
DR, PerCP-conjugated anti-human HLA-DR, PE-conjugated anti-human
CD38, PE/Cy7-conjugated anti-human PD-L1 (BD Biosciences, Franklin
Lakes, NJ, USA); Human Fc Receptor Binding Inhibitor Purified
(eBioscience, San Diego, CA, USA); Easypure RNA kit (Transgen Biotech,
Beijing, China); Faststart Universal SYBR Green Master (ROX) (Roche,
Basel, Switzerland); and TransScript All-in-One First-Strand cDNA Syn-
thesis SuperMix for qPCR (Transgen Biotech, Beijing, China).
2.2. Isolation of monocytes from peripheral blood
Peripheral blood concentrated lymphocytes of Healthy blood donors
were provided by the Changchun Blood Center, and informed consent
was obtained according to the protocols of the Changchun Blood Center.
Peripheral bloodmononuclear cells (PBMCs) were isolated and purified
by density gradient centrifugation using lymphocyte separation
medium.
2.3. Purity and culture of CD14+ monocytes
The CD14+ cells were isolated and purified using CD14 microbeads.
The purities of the CD14+ cells were determined byflow cytometry, and
the purity was always N90%. A half million purified CD14+ monocytes
were cultured in 96-well flat-bottomed plates with complete RPMI
1640 containing 10% fetal calf serum and 100 IU/mL penicillin and
streptomycin at 37 °C with 5% CO2.
2.4. Flow cytometry
Cell staining and analyses were performed as described previously
[20,21]. In brief, CD14+monocytes were cultured for 2 days in the pres-
ence of HCV core protein (final concentration of 10 μg/mL) or polyI:C
(final concentration of 50 μg/mL) and then resuspended in staining
buffer (phosphate-buffered saline containing 0.5% bovine serum albu-
min) and preincubated with FcR blocking reagent for 15 min at 4 °C.Next, the cells were stained with PE/Cy7-conjugated HLA-DR or
PerCP-conjugated anti-human HLA-DR, PE-conjugated anti-human
CD38, or PE/Cy7-conjugated anti-human PD-L1 and incubated for 20–
40min. The cellswere thenwashedwith staining buffer and resuspend-
ed in phosphate-buffered saline containing 1% paraformaldehyde and
analyzed on a flow cytometer (BD LSRFortessa cell analyzer, USA). The
acquired data were analyzed with FlowJo (Treestar software).
2.5. Analysis of the cytokines
The cytokine concentrations were measured using ELISA kits. One
hundred microliters of supernatant was used for each analysis. All sam-
ples were assayed in duplicate.
2.6. qPCR
The CD14+ monocytes were cultured and treated with HCV core
protein and polyI:C or neutralizing antibodies (the final concentrations
of anti-human IL-10 and IL-1β were 10 ng/μL, anti-human TNF-α was
used at 12.5 ng/μL, and anti-human IFN-α and IFN-β were used at
5 ng/μL, according to the efficiency of neutralization by ELISA). The
cells were then harvested using an Easypure RNA kit and reverse tran-
scribed into complementary DNA (cDNA) per the manufacturer's in-
structions. The cDNAs were amplified by qPCR in a Real-Time PCR
System (Applied Biosystems StepOnePlus™, Life Technologies, USA).
Target gene expression was determined using the comparative cycle
threshold (ΔΔCT) method and normalized to GAPDH. The primers are
shown in Table 1.
2.7. Statistical analysis
Statistical analyses were performed using SPSS 18.0. Differences
were evaluated using one-way analysis of variance (ANOVA), followed
by Bonferroni's multiple-comparison test. p b 0.05 was considered
significant and is indicated by an asterisk (*).
3. Results
3.1. HCV core protein- and polyinosinic acid:polycytodylic acid (polyI:C)-
induced secretion of cytokines in CD14+ monocytes
Monocytes constitute 10–20% of the total PBMCs. Monocytes are
characterized by their phenotypic CD14 expression, commonly called
CD14+ monocytes.
In the present study, we first investigated the expression levels of
TLRs on PBMCs and found that the PBMCs expressed TLR2, TLR3, and
TLR4 (data not shown). Then CD14+ monocytes were separated and
cultured alone, or with β-galactosidase (β-gal as control) or with HCV
core protein and/or polyI:C. Our previous study showed that the peak
secretion of IL-10 occurred on the second day of incubation, but the
peaks of TNF-α, IL-1β and IFN-β secretion occurred on the first day
[22]. Thus, we detected the IL-10 level in the medium collected on the
second day and the levels of TNF-α, IL-1β, and IFN-β in themedium col-
lected on the first day after the addition of HCV core protein or polyI:C.
Our results showed that HCV core protein could induce the secretion of
TNF-α, IL-1β, and IL-10, and polyI:C can induce secretion of type I IFN in
CD14+ monocytes. We also found that HCV core protein inhibited
polyI:C-induced type-I IFN production. However, polyI:C acted syner-
gistically with HCV core protein to induce secretion of IL-10 in the
monocytes but inhibited HCV core protein-induced TNF-α and IL-1β se-
cretion (Fig. 1).3.2. HCV core protein and polyI:C affect the phenotypes of CD14+
monocytes
To further characterize the phenotypes of monocytes induced by
HCV core protein or polyI:C,flowcytometrywasused to determine phe-
notypic expression, including human leukocyte antigen-D related (HLA-
DR), cluster of differentiation 38 (CD38), and programmed death-ligand
1 (PD-L1), which reflect the host's immune response [23,24] related to
HCV persistence [25–32].
We found that the optimal concentrations of HCV core protein and
polyI:C for induction were 10 μg/mL and 50 μg/mL, respectively, and
that the number of dead cells became fewer on day 2, resulting in better
phenotypic expression. Our results also showed that HCV core protein
inhibited HLA-DR expression but upregulated PD-L1 expression. PolyI:C
induced the expression of CD38, HLA-DR, and PD-L1 in CD14+ mono-
cytes. Meanwhile, HCV core protein inhibited polyI:C-induced CD38
and HLA-DR expression. However, HCV core protein synergized withFig. 1. HCV core protein and polyI:C induce cytokines secretion in CD14+ monocytes. CD14+
protein and/or polyI:C. The supernatants were collected on the first day for assessment of TN
graphs indicate the cytokine levels from four independent experiments. Med, medium; HCVc
*p b 0.05, **p b 0.01.polyI:C to upregulate PD-L1 expression in monocytes. Therefore, HCV
core protein and polyI:C could modulate the monocyte phenotypes,
which may alter the monocyte functions (Fig. 2).3.3. HCV core protein and polyI:C modulate the phenotypes of CD14+
monocytes through cytokines
We investigatewhether cytokines involved in the regulation onphe-
notypes of CD14+ monocytes.
Our results indicated HCV core protein- and polyI:C-induced cyto-
kine secretion in CD14+ monocytes. Moreover, these cytokines appear
to modulate the monocyte phenotype. Neutralizing antibodies were
used to demonstrate the direct contribution of specific cytokines to
cell surface marker expression. When IL-10 or TNF-α expression was
blocked, HLA-DR expression increased; but when type I IFN was
blocked, HLA-DR expression decreased. In addition, the expression of
CD38 and PD-L1 was decreased when TNF-α, IL-1β, or type I IFN (Fig.
3) was blocked. Therefore, HCV core protein and polyI:C modulated
the phenotypes of CD14+ monocytes via cytokines.3.4. IL-10 is required for the regulation of cytokines induced by HCV core
protein and polyI:C
Given that cytokines canmodulate cell phenotypes, next we studied
the interaction of IL-10 and other cytokines. Our results revealed
that blocking of IL-10 resulted in increased levels of TNF-α, IL-1β, and
IFN-β. On the other hand the IL-10 level was decreased when TNF-α,
IL-1β, or type I IFN was blocked (Fig. 4A). That is, TNF-α, IL-1β, or type
I IFN induced the production of IL-10, and in turn, IL-10 inhibited the
secretion of TNF-α, IL-1β, and type I IFN. The quantitative detection of
cytokine mRNAs was consistent with the detected protein levels
(Fig. 4B).monocytes were separated and cultured alone or with β-gal (control) or with HCV core
F-α, IL-1β, and IFN-β and on the second day for IL-10, as determined by ELISA. The bar
, HCV core protein; PIC, polyI:C. The error bars represent the standard error of the mean.
Fig. 2.HCV core protein and polyI:C modulate the phenotypes of CD14+monocytes. CD14+monocytes were separated and cultured alone or with β-gal or with HCV core protein and/or
polyI:C for 2 days. The cells were then collected and stainedwith PE/Cy7-conjugated HLA-DR, PE-conjugated anti-human CD38, or PE/Cy7-conjugated anti-human PD-L1 and analyzed by
flow cytometry. The histograms (A) and bar graphs indicate the mean fluorescence intensities (MFIs) (B) of four independent experiments. Med, medium; HCVc, HCV core protein;
PIC:polyI:C. The error bars represent the standard error of the mean. *p b 0.05, **p b 0.01, and ns indicates nonsignificant.3.5. IL-10 regulates the secretion of TNF-α and IL-1β by inhibiting nuclear
factor (NF)-κB and the production of type I IFN by inhibiting STAT1 and
interferon regulatory factor 1 (IRF1)
We further studied the immunomodulatory mechanism of IL-10.
Several candidate transcription factors that are likely involved in IL-10
production by macrophages have been described [33–36]. Our results
revealed that the expression levels of NFκB, STAT1 and IRF1 were in-
creased when IL-10 was blocked, as assessed by quantitative polymer-
ase chain reaction (qPCR); however, no significant change was
detected in the expression of STAT3 (Fig. 5).Fig. 3. Cytokines modulate the phenotypes of CD14+ monocytes. CD14+ monocytes were s
neutralizing antibodies for 2 days. The cells were then collected and stained with PerCP-conju
L1 and analyzed by flow cytometry. The bar plots of the mean fluorescence intensities (MFI
antibody”while all groups received both HCVc and PIC. The error bars represent the standardIn combination with other studies, our results led us to the conclu-
sion that TNF-α, IL-1β, and type I IFN induced IL-10 secretion and that
IL-10 subsequently inhibited type I IFN production by downregulating
STAT1 and IRF1, thus inhibiting the secretions of TNF-α and IL-1β by
inhibiting NFκB. These factors form a regulatory network centered on
IL-10.
4. Discussion
In this study, we examined whether HCV core protein and polyI:C
interact with TLRs on monocytes or modulate the biological functionseparated and cultured with HCV core protein and polyI:C in the presence or absence of
gated HLA-DR, PE-conjugated anti-human CD38, or PE/Cy7-conjugated anti-human PD-
s) of seven independent experiments are shown. W/O stands for “without neutralizing
error of the mean. *p b 0.05, **p b 0.01, ***p b 0.001, and ns indicates nonsignificant.
Fig. 4. IL-10 is required for regulating cytokine expression. CD14+monocyteswere separated and culturedwith HCVc and polyI:C in the presence or absence of neutralizing antibodies for
1 or 2 days. The supernatantswere then collected and analyzed by ELISA. The bar plots indicate the levels of cytokines from four independent experiments (A). TheCD14+monocyteswere
separated and culturedwith HCVc and polyI:C in the presence or absence of neutralizing antibodies for approximately 10 h; the cells were then collected, and the RNAwas extracted. The
expression of IL-10, TNF-α, IL-1β, and IFN-βmRNAs was assessed by qPCR. The expression levels were normalized with GAPDH, and the fold inductions were calculated relative to the
untreated controls (B). W/O stands for “without neutralizing antibody” while all groups received both HCVc and PIC. The error bars represent the standard error of the mean. *p b 0.05,
**p b 0.01, ***p b 0.001, and ns indicates nonsignificant.
Fig. 5. IL-10 regulates cytokine secretion through negative feedback. CD14+ monocytes
were separated and cultured with HCVc and polyI:C in the presence or absence of
neutralizing antibodies for 10 h; the cells were then collected, and the RNA was
extracted. The expression of STAT1, STAT3, NFκB, and IRF1 mRNA was assessed by RT-
PCR. The expression levels were normalized with GAPDH, and the fold inductions were
calculated relative to the untreated controls. W/O stands for “without neutralizing
antibody” while all groups received both HCVc and PIC. The error bars represent the
standard error of the mean. *p b 0.05, and ns indicates nonsignificant.of monocytes that might directly or indirectly contribute to persistent
HCV infection. Many studies showed that HCV core protein bound to
TLR2 [37,38], while polyI:C could activate TLR3 [39]. We found that
TLR2, TLR3, and TLR4 were expressed on purified CD14+ monocytes
(data not shown). Our results also showed that HCV core protein in-
duced the secretion of the inflammatory cytokines TNF-α and IL-1β as
well as the immunomodulatory cytokine IL-10. Meanwhile, polyI:C in-
duced type I IFN, which is currently used for treating chronic HCV
infection.
Cytokines can regulate both phenotypes and functions of cells. IL-37
induces a phenotypic shift in human acutemonocytic leukemia-derived
macrophages toward a high-CD206+ and low-CD86+macrophage sub-
type [40]. IL-15 strongly induces the expression of CD69 and CD54 in ap-
proximately 30% of natural killer cell subsets and downregulates CD62L
expression, which is indicative of functional activation [41]. Monocytes
that had been treated with IL-10 in vitro had significantly decreased
HLA-DR expression, thus resulting in expansion of the CD14+HLA-
DRlow/− population [42]. Our results revealed that TNF-α, IL-1β, IL-10
and IFN-βinduced by HCV core protein and polyI:C appeared to modu-
late the expression of HLA-DR, CD38 and PD-L1, andmight alter their bi-
ological functions.
Most of important, IL-10 appeared to play a central role in the regu-
latory circuit of inflammatory and antiviral cytokines. we found that IL-
10 not only inhibited the production of TNF-α and IL-1β induced by
HCV core protein but also reduced the secretion of type I IFN stimulated
by polyI:C. IL-10 may limit hepatic inflammation and injury, but it also
potentially slows down HCV infection clearance. Interestingly, we also
found that TNF-α, IL-1β and type I IFN elevated IL-10 expression,
which in a negative feedback mechanism reduced the production of
TNF-α, IL-1β, and type I IFN. Our findings are in agreement with pub-
lished data that the production and signaling pathway of type I IFN
are involved in lipopolysaccharide-induced IL-10 production that subse-
quently suppresses proinflammatory cytokine genes [19].
To gain insight into themechanisms of IL-10 that regulates these cy-
tokines, several candidate transcription factors have been described.
One study reported that type I IFN induced the production of IL-10
and subsequent STAT3 phosphorylation in murine bone-marrow-de-
rived macrophages and additionally inhibited the expression of proin-
flammatory genes [19]. Another study has found that IL-10 inhibits
the expression of both IFN-α- and IFN-γ-induced genes by suppressing
tyrosine phosphorylation of STAT1 [43].We cultured CD14+monocytes
in the presence of HCV core protein and polyI:C. We found that NFκB,
STAT1, and IRF1 were a few components that regulate IL-10. Our results
suggest that IL-10might inhibit NFκB, which leads to the suppression of
TNF-α and IL-1βwhile downregulating STAT1 and IRF1, which reduces
the type I IFN level. However, the expression of STAT3was not affected.
We believe that this difference was attributable to a species difference.In conclusion, peripheral monocytes secreted TNF-α, IL-1β, and type
I IFN upon induction with HCV core protein and polyI:C. All three cyto-
kines increased IL-10 production, which in a negative feedback mecha-
nism inhibited the expression of proinflammatory cytokines and type I
IFN. Our results suggested that IL-10 countered hepatic inflammation
and clearance of HCV infection and that it may represent a factor con-
tributing to the persistence of HCV infection.
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